SCHEMBL4068860

SCHEMBL4068860

CC1CC(C(CC(O)[CH]Cc2cccnc2)C(=O)NO)CC(C(N)=O)O1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.36
SIRT2 Q8IXJ6 1/20 0.36
SIRT1 Q96EB6 1/20 0.36
ROCK2 O75116 4/20 0.33
RECQL P46063 1/20 0.33
ALDH1A1 P00352 1/20 0.33
PKM P14618 1/20 0.32
KMT2A Q03164 1/20 0.32
CYP2C9 P11712 2/20 0.32
TSHR P16473 1/20 0.32
MAPK1 P28482 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C19 P33261 1/20 0.32
TBXAS1 P24557 2/20 0.32
VNN1 O95497 1/20 0.32
HDAC3 O15379 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC2 Q92769 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4069101 0.79 C3AR1 (0.48)
SCHEMBL4068864 0.78 CCR1 (0.44) CCR1RECQLALDH1A1PKMKMT2A
SCHEMBL4072866 0.70 PKM (0.39) RECQLPKMKMT2ACYP2C9TSHR
SCHEMBL4064703 0.64 VNN1 (0.41) CCR1SIRT2SIRT1RECQLALDH1A1
SCHEMBL3837103 0.63 CCR1 (0.51) CCR1TSHR
SCHEMBL4069111 0.63 C3AR1 (0.45) CCR1
SCHEMBL4069430 0.62 EPHX1 (0.38)
SCHEMBL4060993 0.62 CCR1 (0.36) CCR1KMT2ATSHRCYP2C19
SCHEMBL4043128 0.62 PKM (0.48) ALDH1A1PKMKMT2AHDAC3HDAC1
SCHEMBL4067524 0.62 NPC1 (0.40) ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0966443-B1 HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1-ALPHA BINDING TO ITS CCR1 RECEPTOR PFIZER (US) 2009-01-28 EP disclosed
US-20020198207-A1 Novel Hexanoic acid derivatives KATH JOHN CHARLES (US) 2002-12-26 US disclosed
EP-0966443-A1 HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1-ALPHA BINDING TO ITS CCR1 RECEPTOR PFIZER INC. (US) 1999-12-29 EP disclosed
WO-1998038167-A1 HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1-ALPHA BINDING TO ITS CCR1 RECEPTOR PFIZER INC. (US) 1998-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198207-A1 Novel Hexanoic acid derivatives HCAR3, HCAR1, FFAR1 CCR1 21/4885SIRT2 3062/4885SIRT1 3492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.